CR20210559A - Anticuerpos anti-sema3a y sus usos para tratar enfermedades oculares - Google Patents
Anticuerpos anti-sema3a y sus usos para tratar enfermedades ocularesInfo
- Publication number
- CR20210559A CR20210559A CR20210559A CR20210559A CR20210559A CR 20210559 A CR20210559 A CR 20210559A CR 20210559 A CR20210559 A CR 20210559A CR 20210559 A CR20210559 A CR 20210559A CR 20210559 A CR20210559 A CR 20210559A
- Authority
- CR
- Costa Rica
- Prior art keywords
- ocular diseases
- treating eye
- sema3a
- antibodies
- sema3a antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente invención se refiere a anticuerpos y fragmentos de estos que actúan sobre semaforina 3A (Sema3A). Más específicamente, se divulgan anticuerpos anti-Sema3A y métodos de uso para el tratamiento de varias enfermedades o trastornos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19173454 | 2019-05-09 | ||
PCT/EP2020/062802 WO2020225400A1 (en) | 2019-05-09 | 2020-05-08 | Anti-sema3a antibodies and their uses for treating eye or ocular diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20210559A true CR20210559A (es) | 2021-12-23 |
Family
ID=66476463
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20210559A CR20210559A (es) | 2019-05-09 | 2020-05-08 | Anticuerpos anti-sema3a y sus usos para tratar enfermedades oculares |
Country Status (22)
Country | Link |
---|---|
US (2) | US11267880B2 (es) |
EP (1) | EP3966239A1 (es) |
JP (2) | JP7314310B2 (es) |
KR (1) | KR20220007128A (es) |
CN (1) | CN113795509A (es) |
AR (1) | AR122266A1 (es) |
AU (1) | AU2020267874A1 (es) |
BR (1) | BR112021019854A2 (es) |
CA (1) | CA3137377A1 (es) |
CL (1) | CL2021002795A1 (es) |
CO (1) | CO2021014768A2 (es) |
CR (1) | CR20210559A (es) |
DO (1) | DOP2021000226A (es) |
EA (1) | EA202193038A1 (es) |
EC (1) | ECSP21082527A (es) |
IL (1) | IL287758A (es) |
JO (1) | JOP20210300A1 (es) |
MA (1) | MA55872A (es) |
MX (1) | MX2021013671A (es) |
PE (1) | PE20220287A1 (es) |
SG (1) | SG11202110842QA (es) |
WO (1) | WO2020225400A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113795509A (zh) | 2019-05-09 | 2021-12-14 | 勃林格殷格翰国际有限公司 | 抗-sema3a抗体及其用于治疗眼或眼部疾病的用途 |
US20220127344A1 (en) * | 2020-10-23 | 2022-04-28 | Boehringer Ingelheim International Gmbh | Anti-sema3a antibodies and their uses for treating a thrombotic disease of the retina |
KR20230162800A (ko) * | 2021-03-30 | 2023-11-28 | 바이엘 악티엔게젤샤프트 | 항-sema3a 항체 및 그의 용도 |
CN116790610A (zh) * | 2023-05-18 | 2023-09-22 | 四川大学 | 一种治疗骨科疾病的基因及以aav为载体的基因治疗药物 |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
US4419446A (en) | 1980-12-31 | 1983-12-06 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant DNA process utilizing a papilloma virus DNA as a vector |
NZ201705A (en) | 1981-08-31 | 1986-03-14 | Genentech Inc | Recombinant dna method for production of hepatitis b surface antigen in yeast |
US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
US4601978A (en) | 1982-11-24 | 1986-07-22 | The Regents Of The University Of California | Mammalian metallothionein promoter system |
US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
DD266710A3 (de) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase |
US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
US4965199A (en) | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
AU632065B2 (en) | 1988-09-23 | 1992-12-17 | Novartis Vaccines And Diagnostics, Inc. | Cell culture medium for enhanced cell growth, culture longevity and product expression |
FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
CA2103059C (en) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
PL174721B1 (pl) | 1992-11-13 | 1998-09-30 | Idec Pharma Corp | Przeciwciało monoklonalne anty-CD20 |
US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
US6037454A (en) | 1996-11-27 | 2000-03-14 | Genentech, Inc. | Humanized anti-CD11a antibodies |
US5888809A (en) | 1997-05-01 | 1999-03-30 | Icos Corporation | Hamster EF-1α transcriptional regulatory DNA |
US20120322085A1 (en) | 2009-11-05 | 2012-12-20 | Osaka University | Therapeutic agent for autoimmune diseases or allergy, and method for screening for the therapeutic agent |
WO2013005603A1 (ja) | 2011-07-01 | 2013-01-10 | 公立大学法人横浜市立大学 | 結膜におけるアレルギー性炎症の予防及び/又は治療剤 |
WO2014123186A1 (ja) | 2013-02-06 | 2014-08-14 | 公立大学法人横浜市立大学 | 抗セマフォリン3a抗体、並びにこれを用いたアルツハイマー病及び免疫・炎症性疾患の治療 |
US9822367B2 (en) | 2013-02-21 | 2017-11-21 | Rsem, Limited Partnership | Inhibition of SEMA3A in the prevention and treatment of ocular hyperpermeability |
ES2865488T3 (es) | 2014-09-05 | 2021-10-15 | Rsem Lp | Composiciones y métodos para el tratamiento y la prevención de la inflamación |
US10604571B2 (en) | 2015-10-27 | 2020-03-31 | Samsung Life Public Welfare Foundation | Antibody to human and mouse SEMA3A and use thereof |
WO2017074013A1 (ko) | 2015-10-27 | 2017-05-04 | 사회복지법인 삼성생명공익재단 | 인간 및 마우스 sema3a에 교차결합하는 항체 및 그의 용도 |
KR101854529B1 (ko) | 2015-10-27 | 2018-05-04 | (주) 팬젠 | 인간 및 마우스 Sema3A에 교차결합하는 항체 및 그의 용도 |
CN113795509A (zh) | 2019-05-09 | 2021-12-14 | 勃林格殷格翰国际有限公司 | 抗-sema3a抗体及其用于治疗眼或眼部疾病的用途 |
-
2020
- 2020-05-08 CN CN202080034499.1A patent/CN113795509A/zh active Pending
- 2020-05-08 CR CR20210559A patent/CR20210559A/es unknown
- 2020-05-08 JP JP2021565942A patent/JP7314310B2/ja active Active
- 2020-05-08 WO PCT/EP2020/062802 patent/WO2020225400A1/en active Application Filing
- 2020-05-08 US US16/869,618 patent/US11267880B2/en active Active
- 2020-05-08 PE PE2021001846A patent/PE20220287A1/es unknown
- 2020-05-08 CA CA3137377A patent/CA3137377A1/en active Pending
- 2020-05-08 SG SG11202110842QA patent/SG11202110842QA/en unknown
- 2020-05-08 EP EP20723153.1A patent/EP3966239A1/en active Pending
- 2020-05-08 MX MX2021013671A patent/MX2021013671A/es unknown
- 2020-05-08 BR BR112021019854A patent/BR112021019854A2/pt unknown
- 2020-05-08 MA MA055872A patent/MA55872A/fr unknown
- 2020-05-08 AR ARP200101337A patent/AR122266A1/es unknown
- 2020-05-08 EA EA202193038A patent/EA202193038A1/ru unknown
- 2020-05-08 KR KR1020217040292A patent/KR20220007128A/ko unknown
- 2020-05-08 JO JOP/2021/0300A patent/JOP20210300A1/ar unknown
- 2020-05-08 AU AU2020267874A patent/AU2020267874A1/en active Pending
-
2021
- 2021-10-25 CL CL2021002795A patent/CL2021002795A1/es unknown
- 2021-11-01 DO DO2021000226A patent/DOP2021000226A/es unknown
- 2021-11-01 IL IL287758A patent/IL287758A/en unknown
- 2021-11-02 CO CONC2021/0014768A patent/CO2021014768A2/es unknown
- 2021-11-18 EC ECSENADI202182527A patent/ECSP21082527A/es unknown
-
2022
- 2022-01-25 US US17/583,245 patent/US20220144929A1/en not_active Abandoned
-
2023
- 2023-07-12 JP JP2023114243A patent/JP2023130473A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JP7314310B2 (ja) | 2023-07-25 |
JP2023130473A (ja) | 2023-09-20 |
CO2021014768A2 (es) | 2021-11-19 |
US20220144929A1 (en) | 2022-05-12 |
MX2021013671A (es) | 2021-12-10 |
AU2020267874A1 (en) | 2021-10-28 |
JP2022531698A (ja) | 2022-07-08 |
WO2020225400A1 (en) | 2020-11-12 |
ECSP21082527A (es) | 2021-12-30 |
DOP2021000226A (es) | 2021-12-15 |
EP3966239A1 (en) | 2022-03-16 |
CN113795509A (zh) | 2021-12-14 |
TW202108621A (zh) | 2021-03-01 |
CA3137377A1 (en) | 2020-11-12 |
SG11202110842QA (en) | 2021-10-28 |
JOP20210300A1 (ar) | 2023-01-30 |
AR122266A1 (es) | 2022-08-31 |
KR20220007128A (ko) | 2022-01-18 |
US11267880B2 (en) | 2022-03-08 |
CL2021002795A1 (es) | 2022-08-05 |
PE20220287A1 (es) | 2022-02-25 |
US20200385446A1 (en) | 2020-12-10 |
EA202193038A1 (ru) | 2022-03-30 |
IL287758A (en) | 2022-01-01 |
MA55872A (fr) | 2022-03-16 |
BR112021019854A2 (pt) | 2022-02-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021013671A (es) | Anticuerpos anti-sema3a y sus usos para tratar enfermedades oculares. | |
AU2018338314A1 (en) | Protein degraders and uses thereof | |
MX2020009366A (es) | Anticuerpos anti-cd73 y usos de los mismos. | |
MX2022005253A (es) | Anticuerpos neutralizantes de poliomavirus. | |
EP4183806A3 (en) | Glycan-interacting compounds and methods of use | |
CR20220626A (es) | Compuestos para el tratamiento de enfermedades y trastornos asociados a braf | |
MX2020008122A (es) | Anticuerpos anti-pd-1. | |
EA201992143A1 (ru) | Биспецифические антитела, перенаправляющие т-клетки, для лечения egfr-положительных раковых заболеваний | |
PH12017502020A1 (en) | Antibodies targeting bone morphogenetic protein 9 (bmp9) and methods therefor | |
MX2020007555A (es) | Anticuerpos potenciadores del factor h y usos de los mismos. | |
ZA201907371B (en) | Methods and compositions for treating allergic ocular diseases | |
MX2021002652A (es) | Uso de inhibidores de caseina-cinasa 1 para el tratamiento de enfermedades vasculares. | |
WO2019165158A8 (en) | Il-6 inhibitors and methods of treatment | |
EA202092593A1 (ru) | Белки, связывающие каннабиноидный рецептор 1-го типа (cb1), и их применение | |
EA202191058A1 (ru) | Антитела против муцина-16 и способы их применения | |
PH12019500434A1 (en) | Anti-gm-csf antibodies and uses thereof | |
MX2020012014A (es) | Conjugados y derivados de prostaglandina para tratar el glaucoma y la hipertension ocular. | |
MX2022003544A (es) | Anticuerpos anti-nrp1a y sus usos para tratar enfermedades oculares. | |
MX2023005591A (es) | Metodos de tratamiento de enfermedades y trastornos. | |
MX2020013243A (es) | Anticuerpos anti-il-22, fragmentos de anticuerpo, sus inmunoconjugados y usos de los mismos. | |
MX2023004643A (es) | Anticuerpos anti-sema3a y sus usos para tratar una enfermedad trombotica de la retina. | |
WO2019150050A8 (fr) | Dimères de variants du facteur x | |
ECSP22020678A (es) | Anticuerpos anti-nrp1a y sus usos para tratar enfermedades oculares | |
MX2021009767A (es) | Moleculas de union de fmcr y usos de las mismas. | |
MX2022006751A (es) | Minitrampas de vegf y metodos de uso de las mismas. |